Abstract:Objectives: Platinum sensitivity is the most important predictor of prognosis and response to further treatment in ovarian cancer, while it is still roughly prejudged in line with the interval of progression free survival in clinical practice. Realizing individualized precision medicine require refining predictive model that could enable selection of patients who would benefit from platinum-based or non-platinum containing therapy. The study aims to identify and integrate novel biomarkers for prediction of platinum sensitivity in ovarian cancer. Methods: 60 patients with epithelial ovarian cancer receiving standard initial treatment were recruited from 2016 to 2019. According to interval of progress free survival (PFS), 44 patients (PFS>6 months) and 16 patients (PFS≤6 months) were defined as platinum-sensitive and platinum-resistant recurrence, respectively. We performed next generation sequencing (NGS) analysis of the entire genomic features of ovarian tumor tissue samples obtained from debulking surgery. Multiple genomic variation were compared between platinum sensitive and resistant patients, including single-nucleotide variant (SNV), single base or indel signature, focal copy number variation (CNV), mutational clonality, whole-genome duplication (WGD), and co-variation in DNA damage repair (DDR) pathways. Collectively, a multi-factor-based prediction model was trained and validate with Lasso regression. Results: Analysis of single base signature revealed that the contribution of SBS10a in platinum-sensitive patients was significantly higher than that of platinum-resistant patients (P<0.05). Consistently, patients with SBS10a signature exhibited higher platinum sensitivity (P<0.01) and longer PFS than SBS10a negative patients (15.8m vs 10.1m, P<0.05). Focal CNVs involved in DDR pathways which believed to play a pivotal role in platinum response were emphatically investigated. The results demonstrated the incidence of FAM175A LOH in platinum-sensitive patients was significantly higher than that of platinum-resistant patients (P<0.01), meanwhile the median PFS of patients with FAM175A LOH was significantly longer than patients with wild-type FAM175A (16.5m vs 9.2m, P<0.05). Moreover, patients with WGD showed higher proportion of platinum resistance (P<0.01) and shorter median PFS than patients with normal chromosomal ploidy (9.1m vs 16.47m, p<0.05). Unlucky, there was no marked difference in the distribution of overall SNV or DDR related SNV with top frequency between platinum sensitive and resistant cases. Patients with clonal DDR mutations or co-variation in DDR pathways exhibited higher proportion of platinum response and longer PFS than patients without these variations, but the differences were not statistically significant. By integrating of SBS10a, FAM175A LOH and WGD which showed significant differences in platinum sensitivity in univariate analyses, a lasso regression model was employed to train and validate with all patients. A promising performance with the AUC value 0.864 was observed in ROC curve, suggesting the predictive performance of this model was favorable. Graphical Abstract View Large Image Figure Viewer Download Hi-res image Conclusions: Our study successfully established a prediction model containing three novel biomarkers FAM175A LOH, SBS10a mutation and WGD through in-depth mining of NGS, which has an extremely potential of predictive value for platinum sensitivity in epithelial ovarian cancer. However, it requires larger cohort for further validation. Platinum sensitivity is the most important predictor of prognosis and response to further treatment in ovarian cancer, while it is still roughly prejudged in line with the interval of progression free survival in clinical practice. Realizing individualized precision medicine require refining predictive model that could enable selection of patients who would benefit from platinum-based or non-platinum containing therapy. The study aims to identify and integrate novel biomarkers for prediction of platinum sensitivity in ovarian cancer. 60 patients with epithelial ovarian cancer receiving standard initial treatment were recruited from 2016 to 2019. According to interval of progress free survival (PFS), 44 patients (PFS>6 months) and 16 patients (PFS≤6 months) were defined as platinum-sensitive and platinum-resistant recurrence, respectively. We performed next generation sequencing (NGS) analysis of the entire genomic features of ovarian tumor tissue samples obtained from debulking surgery. Multiple genomic variation were compared between platinum sensitive and resistant patients, including single-nucleotide variant (SNV), single base or indel signature, focal copy number variation (CNV), mutational clonality, whole-genome duplication (WGD), and co-variation in DNA damage repair (DDR) pathways. Collectively, a multi-factor-based prediction model was trained and validate with Lasso regression. Analysis of single base signature revealed that the contribution of SBS10a in platinum-sensitive patients was significantly higher than that of platinum-resistant patients (P<0.05). Consistently, patients with SBS10a signature exhibited higher platinum sensitivity (P<0.01) and longer PFS than SBS10a negative patients (15.8m vs 10.1m, P<0.05). Focal CNVs involved in DDR pathways which believed to play a pivotal role in platinum response were emphatically investigated. The results demonstrated the incidence of FAM175A LOH in platinum-sensitive patients was significantly higher than that of platinum-resistant patients (P<0.01), meanwhile the median PFS of patients with FAM175A LOH was significantly longer than patients with wild-type FAM175A (16.5m vs 9.2m, P<0.05). Moreover, patients with WGD showed higher proportion of platinum resistance (P<0.01) and shorter median PFS than patients with normal chromosomal ploidy (9.1m vs 16.47m, p<0.05). Unlucky, there was no marked difference in the distribution of overall SNV or DDR related SNV with top frequency between platinum sensitive and resistant cases. Patients with clonal DDR mutations or co-variation in DDR pathways exhibited higher proportion of platinum response and longer PFS than patients without these variations, but the differences were not statistically significant. By integrating of SBS10a, FAM175A LOH and WGD which showed significant differences in platinum sensitivity in univariate analyses, a lasso regression model was employed to train and validate with all patients. A promising performance with the AUC value 0.864 was observed in ROC curve, suggesting the predictive performance of this model was favorable. Our study successfully established a prediction model containing three novel biomarkers FAM175A LOH, SBS10a mutation and WGD through in-depth mining of NGS, which has an extremely potential of predictive value for platinum sensitivity in epithelial ovarian cancer. However, it requires larger cohort for further validation.

Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer

MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment

Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer

Proteomic Biomarker Predicts Therapeutical Effects of Oxaliplatin Combining with Fluoropyrimidine in Metastatic Gastric Cancer Patients by the SELDI-proteinchip Platform.

Prognostic Role of Circulating Exosomal Mir-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.

Development and Validation of a Predictive Model for Resistance to Platinum-Based Chemotherapy in Patients with Ovarian Cancer through Proteomic Analysis

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients

Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer Via Integrated Bioinformatics Analysis.

Prediction of Platinum Resistance for Advanced High-Grade Serous Ovarian Carcinoma Using MRI-based Radiomics Nomogram

NGS-based Multi-Factor Prediction Model of Platinum Sensitivity for Epithelial Ovarian Cancer

Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer

A risk model of gene signatures for predicting platinum response and survival in ovarian cancer

Novel MicroRNA-Regulated Transcript Networks Are Associated with Chemotherapy Response in Ovarian Cancer

Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis

Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI

High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma

Plasma Micrornas Predict Chemoresistance in Patients with Metastatic Breast Cancer.

A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients

Prognostic Model Construction Based on Platinum-Free Interval in Ovarian Cancer and Its Implication for Chemotherapy Resistance

Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer